Valor IV Pharma Holdings, LLC
Known title: 10% OwnerCIK: 0001821186
Associated companies
Transaction History
| HRMY | ▼ Sell | Other | 6,618,033 | — | 8/28/2025 | View on chart |
| HRMY | ▼ Sell | Open Market | 600,000 | $18.2M | 11/5/2024 | View on chart |
| HRMY | ▼ Sell | Open Market | 4,000,000 | $121.2M | 11/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
HRMY Reports New Phase 3 Data and Maintains Positive Analyst Outlook
HRMY shared new Phase 3 data at the European Narcolepsy Days, adding to its pipeline. Analysts remain upbeat, with Needham keeping a positive stance and a $50 target. The Wakix franchise also offers multiple value drivers. Shares rose 48% recently, yet the stock still trades below its 52‑week low.
HRMY Reports New Phase 3 Data and Maintains Positive Analyst Outlook. HRMY shared new Phase 3 data at the European Narcolepsy Days, adding to its pipeline. Analysts remain upbeat, with Needham keeping a positive stance and a $50 target. The Wakix franchise also offers multiple value drivers. Shares rose 48% recently, yet the stock still trades below its 52‑week low.